Glympse Bio raises more than $46M in Series B round for biosensor technology

ARCH Venture Partners, biopharma nl, Cambridge Massachusetts, Catalio Capital Management, CRV, Daily, Diagnostics, DNS Capital, Gilead Sciences, Glympse Bio, GreatPoint Ventures, LS Polaris Innovation Fund, NASH, New Leaf Venture Partners, nonalcoholic steatohepatitis, Section 32, Startups, SYN, Temasek, Top Story, Waterman Ventures / July 15, 2020

The company is developing biosensors, initially for NASH, that could be used in place of liver biopsy and have applicability in development of drugs for the disease.